Cooley's leadership in corporate representation and mergers and acquisition counseling for life science companies provides a deep foundation of experience upon which we have established a dedicated team of corporate partnering and licensing attorneys.
Our senior team members are internationally recognized as being the best in their field. Many of our professionals are backed by a wealth of supporting experience, having been pharmaceutical marketing specialists, business consultants, financial leaders, biotech researchers and in-house counsel at life science companies.
We have a solid understanding of the drug development and regulatory environment, expertise in early-stage R&D, late stage product deals, particular expertise in late-stage compound deals and specific knowledge of the sensitivities surrounding commercialization issues such as:
- Indication splitting
- Off-label sales
- Product bundling
Key Facts
- 25 dedicated professionals exclusively focused on corporate partnering, licensing and other commercial transactions specific to the life science industry
- Nearly one third of the attorneys in the group have advanced degrees in relevant scientific disciplines
- Many of the attorneys speak multiple languages and work extensively on cross-border transactions
Rankings and Accolades
Cooley clients are in bold.
- Affymax (Hematide)/ Takeda collaboration named "2007 Deal of Distinction" by the Licensing Executives Society
- Protein Design Labs (PDL)/Biogen Idec collaboration named "2006 Deal of Distinction" by the Licensing Executives Society
- Allicense "Breakthrough Deal of the Year" awarded to Cooley transactions:
- 2007: Affymax/ Takeda
- 2006: Nuvelo/ Bayer
- 2003: Eli Lilly/Amylin (also nominated: GSK/Exelixis)
- 2002: Eli Lilly/ISIS Pharmaceuticals (also nominated: BMS/Exelixis)
- 2000: Innovex/CV Therapeutics
- Ranked #1 in Life Sciences by Chambers USA: America's Leading Lawyers for Business in 2007 and 2008
Related Practices
Related Industries
|